Durvalumab gets FDA breakthrough status for bladder cancer
Durvalumab gets FDA breakthrough status for bladder cancer
17 Feb 2016The U.S. Food and Drug Administration has granted breakthrough therapy designation to AstraZeneca's biggest new drug hope durvalumab as a treatment in bladder cancer, the drug maker reported.
The experimental medicine is a so-called PD-L1 therapy that fights cancer by boosting the immune system. Breakthrough therapy designation expedites the development and review of medicines intended to treat serious or life-threatening diseases.
Durvalumab is also being developed as a treatment for lung, head and neck, gastric, pancreatic, liver and blood cancers.
Source: Reuters